IFITM3 and hepatocellular carcinoma: Additionally, patients with metastatic liver cancer exhibit higher IFITM3 mRNA expression levels.17 Other studies have identified IFITM3 as an oncogene in HCC.28 Mechanistically, some research suggests that IFITM3 may modulate the Wnt/β-catenin signaling pathway and engage in the G0/G1 checkpoint, influencing the cell cycle during tumor development.29